ASSESSMENT OF THE COST-EFFECTIVENESS OF SECUKINUMAB VERSUS RISANKIZUMAB FOR THE TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN THE UK

被引：0
|
作者：
Moreno, S. [1 ]
Walsh, S. [2 ]
Khanna, P. J. [3 ]
Jain, M. [3 ]
Tanova-Yotova, N. [4 ]
机构：
[1] Novartis Pharma AG, Basel, Switzerland
[2] Novartis Business Serv Ctr, Dublin, Ireland
[3] Novartis Healthcare Pvt Ltd, Hyderabad, Telangana, India
[4] Amaris, Sofia, Bulgaria
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE186
引用
收藏
页码：S89 / S89
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF SECUKINUMAB COMPARED WITH USTEKINUMAB AND ETANERCEPT FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN GREECE
    Tzanetakos, C.
    Kourlaba, G.
    Chatzikou, M.
    Antoniou, C.
    Ioannidis, D.
    Lefaki, I
    Petridis, A.
    Rigopoulos, D.
    Roussaki-Schulze, A.
    Sotiriadis, D.
    Maniadakis, N.
    VALUE IN HEALTH, 2016, 19 (07) : A569 - A569
  • [2] Cost-effectiveness of secukinumab compared with ustekinumab and etanercept for the treatment of moderate-to-severe plaque psoriasis in Greece
    Tzanetakos, C.
    Kourlaba, G.
    Hatzikou, M.
    Antoniou, C.
    Ioannides, D.
    Lefaki, I.
    Petridis, A.
    Rigopoulos, D.
    Roussaki-Schulze, V.
    Sotiriadis, D.
    Maniadakis, N.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 61 - 62
  • [3] Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: The Chinese Healthcare System Perspective
    Zhang, Jinsui
    Xia, Zemin
    Guo, Wanjie
    Ren, Xiaoxiao
    Liu, Fang
    Ratnaparkhi, Gargi
    Pagada, Amit
    Subramanian, Subhashini
    Hu, Min
    Chen, Wen
    DERMATOLOGY AND THERAPY, 2023, 13 (11) : 2681 - 2696
  • [4] Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: The Chinese Healthcare System Perspective
    Jinsui Zhang
    Zemin Xia
    Wanjie Guo
    Xiaoxiao Ren
    Fang Liu
    Gargi Ratnaparkhi
    Amit Pagada
    Subhashini Subramanian
    Min Hu
    Wen Chen
    Dermatology and Therapy, 2023, 13 : 2681 - 2696
  • [5] Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
    Papp, Kim A.
    Blauvelt, Andrew
    Bukhalo, Michael
    Gooderham, Melinda
    Krueger, James
    Lacour, Jean-Philippe
    Menter, Alan
    Philipp, Sandra
    Sofen, Howard
    Tyring, Stephen
    Berner, Beate R.
    Visvanathan, Sudha
    Pamulapati, Chandrasena
    Bennett, Nathan
    Flack, Mary
    Scholl, Paul
    Padula, Steven J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (16): : 1551 - 1560
  • [6] Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis
    Fioranelli, Massimo
    Roccia, Maria Grazia
    Lotti, Torello
    DERMATOLOGIC THERAPY, 2017, 30 (05)
  • [7] Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy
    Gisondi, Paolo
    Loconsole, Francesco
    Raimondo, Paola
    Ravasio, Roberto
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2021, 8 : 120 - 130
  • [8] Cost-effectiveness of treatment for moderate-to-severe psoriasis
    Hankin, CS
    Feldman, SR
    Pearce, D
    VALUE IN HEALTH, 2004, 7 (06) : 654 - 654
  • [9] Risankizumab in moderate-to-severe plaque psoriasis
    Serrano, Linda
    Maloney, Victoria
    Gordon, Kenneth B.
    IMMUNOTHERAPY, 2019, 11 (16) : 1357 - 1370
  • [10] Evaluating the cost-effectiveness of secukinumab in moderate-to-severe psoriasis: a Japanese perspective
    Igarashi, Atsuyuki
    Igarashi, Ataru
    Graham, Christopher N.
    Gilloteau, Isabelle
    Tani, Yumiko
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (01) : 7 - 15
12345